| Date | Title | Description |
| 18.06.2018 | Valeant nosedives on CRL for plaque psoriasis, raising concerns over touted $1B pipeline | Valeant is suffering another hit this morning as the FDA kicked back its application for a drug the pharma giant touted as one of seven “significant” products meant to recharge the company’s revenue.
US regulators gave... |
| 23.06.2017 | OvaScience and Active Biotech name new CEOs, Valeant adds John Paulson to the board | Christopher Kroeger
→ OvaScience struggled hard last year, dropping its CEO, COO and 30% of its staff. Now they have named a new CEO, Christopher Kroeger. Kroeger previously spent over a decade at the venture firm The Aurora Fund... |
| 09.06.2017 | Carlyle, PEP to buy iNova Pharma from Valeant for $930m | Premium
Valeant Pharmaceuticals International Inc said on Thursday it would sell its iNova Pharmaceuticals business for $930 million, as Chief Executive Joseph Papa steps up efforts to slash the embattled Canadian drugmaker’s enormous debt ... |
| 07.06.2017 | Term Sheet — Wednesday, June 7 | 500
Hello, it’s Fortune 500 day! The 2017 list is live here. For 63 years, this list has ranked the largest companies in the U.S. by revenue.
Paid Content You can't secure what you can't see From ExtraHop
KKR got rather dramatically knocked... |
| 06.03.2017 | It's another day of 'good news is bad news' at Bill Ackman's nightmare stock | Here's the good news: Valeant Pharmaceuticals has raised $1.1 billion dollars in asset sales it will use to pay down debt. It's also taking this opportunity to refinance more of its $30 billion outstanding debt load.
Advertisement
That's al... |
| 02.03.2017 | Bill Ackman's nightmare stock is getting stomped for the 2nd day in a row | Bloomberg via Getty Images
Valeant Pharmaceuticals' stock is falling for the second day in a row on news that the company is being probed by the SEC.
Advertisement
Valeant's 10k filing reports that the regulatory agency is investigating the... |
| 11.10.2016 | Huge Valeant price hike on lead poisoning drug sparks anger | A drug used to treat lead poisoning is causing a toxic reaction among hospitals and poison control centers after Valeant Pharmaceuticals jacked up the price more than 2,700 percent in a single year.
At issue is a decades-old, intravenous tr... |
| 25.04.2016 | Valeant has a new CEO whose strength is ‘fostering an ethical culture’ | Pearson was subpoenaed last month to testify before a Senate committee investigating these drug hikes. He’s slated to appear in front of a special committee on aging on April 27 — the third of its kind, in which pharmaceutical companies hav... |
| 09.03.2016 | New Valeant board members raise concerns, analyst says | As Valeant Pharmaceuticals grapples with intensifying scrutiny of its business practices, the drug maker has added three new members to its board, including one from Pershing Square Capital Management, one of its largest shareholders.
The m... |
| 29.02.2016 | Pharmalot, Pharmalittle: Glaxo searching for new CEO, Valeant CEO returns from illness | Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that familiar routine has now returned with a vengeance. Our to-do list is quickly piling up with deadlines, mee... |
| 29.02.2016 | Already facing investor concerns, Valeant hit with another SEC probe | Valeant Pharmaceuticals is being investigated by the US Securities and Exchange Commission in connection with a previously undisclosed probe, a company spokeswoman said. Further details are not known, but the investigation is not connected ... |
| 07.02.2016 | A gutsy move: Valeant runs Super Bowl commercial for Xifaxan | Many figured that the pharmaceutical industry would lay low this year and not advertise during the Super Bowl: Drug pricing remains a sensitive topic to the broader public. And yet Valeant, one of the most scrutinized of the pharmas, chose ... |
| 04.02.2016 | The Shkreli smirk effect: 5 congressional rants from today’s drug pricing hearing | “Turing followed most of the consultant’s advice, except for one glaring exception – you never lowered the price of Daraprim,” Cummings spat. “This email indicates that despite the promises of lowering the price internally, Turing has no de... |
| 16.12.2015 | Lawmaker accuses Valeant of obstructing congressional investigation | Is Valeant Pharmaceuticals obstructing a congressional investigation?
That’s the accusation that one congressman leveled in a letter sent Monday to the drug maker. In his missive, Representative Elijah Cummings, a Democrat from Maryland, no... |
| 19.10.2015 | Morning Read: Cardiology on trial, more Theranos chatter, Valeant Q3 earnings out | The article is a fascinating read: pitting doctors against doctors and taking on the unwritten rules of clinical practices. – The New York Times
VCs are pushing back on the Theranos criticism – largely with the typical defensive tropes like... |
| 20.08.2015 | Morning Read: Valeant wants to buy Sprout in $1B deal, Allscripts and CoverMyMeds collaborate | Allscripts and CoverMyMeds have agreed to partner to help patients receive their prescriptions faster and increase the number of health plans available for Allscripts eAuth software clients.
Allscripts eAuth software enables providers to qu... |
| 21.07.2014 | Allergan cuts 1,500 jobs, faces SEC complaint | Updated July 21, 2014, at 12:40 p.m. EST with additional information on Allergan’s earnings.
Medical device maker Allergan (NYSE:AGN) announced today that it plans to cut 13% of its global workforce and delete some vacancies as the battle h... |
| 14.07.2014 | Allergan renews fight against hostile Valeant takeover | Allergan (NYSE:AGN) went on the offensive again today in its battle against a hostile takeover bid by Valeant Pharmaceuticals and its hedge fund partner, Pershing Square Capital Management, demanding more transparency from Valeant about its... |
| 30.05.2014 | Valeant raises bid to $53B for Allergan | Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) again increased its offer to Allergan (NYSE:AGN) shareholders, hoping to win them over with steep premiums as the company remains stalwart in refusing to open up to acquisition talks.
The new offe... |
| 28.05.2014 | Valeant sweetens Allergan offer by $10 per share | Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) today upped the cash portion of its unsolicited acquisition bid for Allergan (NYSE:AGN) to $49.44 billion, increasing the offer by $10 per share and adding a contingent value right related to Alle... |
| 23.04.2014 | Frenzy of pharma deals resembles 2008, but goal is leaner, more focused businesses | Between Pfizer and AstraZeneca deal rumors followed by a strategic portfolio exchange by GlaxoSmithKline and Novartis and an offer for Allergan this week, it feels like a deal frenzy is underway. When you look at the numbers from the first ... |
| 27.01.2014 | Valeant closes $250M acquisition of Solta Medical | Solta Medical this month became a wholly owned subsidiary of Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) after the completion of a $2.92-per-share tender offer.
Aesthetics devices maker Solta’s products will fold into Valeant’s existing aes... |
| 16.12.2013 | Valeant to pay $250M for Solta Medical | Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) said it agreed to pay $2.92 per share for Solta Medical (NSDQ:SLTM) in a cash deal worth roughly $250 million.
The per-share price is a 40% premium over SLTM’s closing price Dec. 13. News of the p... |
| 17.02.2012 | ACOR’s Neuronex acquisition worth up to $133M; hinges on epilepsy drug | Hawthorne, New York-based Acorda said in regulatory filings that Neuronex’s nasal diazepam, referred to as DZNS, fits into the company’s neurology drug portfolio. Acorda’s top-selling drug is multiple sclerosis treatment Amphyra, which gene... |
| 13.06.2011 | GSK epilepsy drug approved by FDA; classified as a controlled substance | “We believe this product will play a needed role in the management of partial-onset seizures in appropriate patients who are uncontrolled on their current medications,” Susan Hall, head of research and development at Valeant, said in a prep... |
| 03.02.2011 | GlaxoSmithKline sells rights to cold sore drug to Canadian pharma | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 03.02.2011 | Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of Directors | Feb 03 2011
MENLO PARK, California – Corium International, Inc., a privately-held advanced transdermal drug delivery company, today announced the appointment of Dr. Bhaskar Chaudhuri and David L. Greenwood to the Board of Directors. Dr. Ch... |
| 21.01.2011 | GSK epilepsy drug gets European OK; U.S. regulators want more details | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 30.07.2007 | Talecris, a ludicrously large IPO, and the beginning of the end for private equity? | (UPDATED: See below.) Is the air starting to hiss out of the private-equity bubbble? Looking at Talecris Biotherapeutics, a stodgy biotech controlled by private-equity firms Cerberus Capital Management and Ampersand Ventures that filed to r... |
| - | Morning Read: Valeant wants to buy Sprout in $1B deal, Allscripts and CoverMyMeds collaborate | TOP STORIES
Just a few days after winning FDA approval for its female libido enhancing drug Addyi, Sprout Pharmaceuticals has a suitor. Valeant Pharmaceuticals plans to make a $1B deal to acquire the business. The Wall Street Journal cited ... |
| - | Valeant has a new CEO whose strength is ‘fostering an ethical culture’ | Valeant Pharmaceuticals has found a replacement for CEO Michael Pearson: It just poached Joseph Papa, who has resigned as CEO of over-the-counter drugmaker Perrigo. Papa will begin at Valeant in early May, beginning his tenure as Pearson st... |
| - | ACOR’s Neuronex acquisition worth up to $133M; hinges on epilepsy drug | Central nervous system therapies company Neuronex is being acquired by Acorda Therapeutics (NASDAQ:ACOR) in a deal valued at up to $133 million, yielding to Acorda a novel epilepsy treatment nearly ready for filing with the U.S. Food and Dr... |
| - | GSK epilepsy drug approved by FDA; classified as a controlled substance | GlaxoSmithKline (NYSE:GSK) and drug partner Valeant Pharmaceuticals (NYSE:VRX) have received U.S. Food and Drug Administration approval on a new epilepsy drug, but it must be classified as a controlled substance and regulators are also requ... |
| - | Morning Read: Cardiology on trial, more Theranos chatter, Valeant Q3 earnings out | TOP STORIES
The case of a cardiology practice in northern Indiana will prove to be a showdown over waste and medical procedures.
“Cardiology, whether we like it or not, is generally a big moneymaker for hospitals,” said Dr. Steven Nissen, c... |
| - | GSK epilepsy drug gets European OK; U.S. regulators want more details | A new epilepsy treatment co-developed by GlaxoSmithKline (NYSE:GSK) and a partner has received preliminary approval in Europe. However, its future in the United States remains up in the air.
GSK and drug development partner Valeant Pharmace... |
| - | A gutsy move: Valeant runs Super Bowl commercial for Xifaxan | Valeant Pharmaceuticals let loose its anthropomorphized, antsy “Gut Guy” during the third quarter of the 2016 Super Bowl. This ad for diarrhea drug Xifaxan is already making a splash: You can see the commercial here.
But, considering the st... |
| - | Frenzy of pharma deals resembles 2008, but goal is leaner, more focused businesses | Between Pfizer and AstraZeneca deal rumors followed by a strategic portfolio exchange by GlaxoSmithKline and Novartis and an offer for Allergan this week, it feels like a deal frenzy is underway. When you look at the numbers from the first ... |
| - | GlaxoSmithKline sells rights to cold sore drug to Canadian pharma | GlaxoSmithKline has sold the rights to topical drug Zovirax to a Canadian pharmaceutical company for $300 million.
Valeant Pharmaceuticals (NYSE:VRX) said its subsidiary Biovail Laboratories has signed agreements to acquire all U.S. and Can... |
| - | The Shkreli smirk effect: 5 congressional rants from today’s drug pricing hearing | Martin Shkreli, as predicted, invoked the Fifth Amendment and kept uncharacteristically quiet during today’s House of Representatives hearing on drug prices. However, his demeanor alone ruffled congressional feathers – with Rep. John Mica (... |